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Abstract 
Introduction: To clarify the difference between system A and L amino acid transport imaging in PET 
clinical imaging, we focused on the use of α-[N-methyl-11C]-methylaminoisobutyric acid ([11C]MeAIB), 
and compared it with [S-methyl-11C]-L-methionine ([11C]MET). The aim of this study was to assess the 
correlation of accumulation of these two radioactive amino acid analogs with expression of amino acid 
transporters and cell proliferative activity in carcinoma cells. 
Methods: Amino acid uptake inhibitor studies were performed in four human carcinoma cells (epidermal 
carcinoma A431, colorectal carcinoma LS180, and lung carcinomas PC14/GL and H441/GL) using the 
radioisotope analogs [3H]MET and [14C]MeAIB. MeAIB was used to inhibit the A system and 
2-amino-2-norbornane-carboxylic acid (BCH) was used to inhibit the L system. The carcinoma gene 
expression levels of a number of amino acid transporters were measured by microarray and quantitative 
polymerase chain reaction. Carcinoma proliferative activity was assessed using accumulation of 
[methyl-3H]-3'-deoxy-3'-fluorothymidine ([3H]FLT). 
Results and Conclusion: [14C]MeAIB uptake occurred principally via a Na+-dependent A type mechanism 
whereas [3H]MET uptake, which occurred predominantly via a Na+-independent L type mechanism 
although other transporters were also utilized depending on cell type. There was no correlation between 
[3H]MET uptake and total system L amino acid transporter (LAT) expression. In contrast, [14C]MeAIB 
uptake strongly correlated with total system A amino acid transporter (SNAT) expression and proliferative 
activity in this preliminary study using four human carcinoma cell lines. Carcinoma proliferative activity 
also correlated with total SNAT expression. 
Advances in Knowledge and Implications for Patient Care: Because there is a significant correlation 
between the accumulation of [14C]MeAIB and the gene expression level of total SNAT as well as the 
accumulation of [3H]FLT, it is suggested that use of the analog [11C]MeAIB in PET may provide an 
indication of tumor cell proliferative activity. [11C]MeAIB is therefore expected to be very useful in PET 
imaging. 
 
[Key Words] MeAIB, Amino acid transporters, System A, MET, FLT, proliferative activity 
1. Introduction 
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), an analog of glucose, is the most commonly used 
radiopharmaceutical in positron emission tomography (PET)-CT imaging [1]. PET-CT imaging is based 
on the preferential uptake of [18F]FDG in tumor cells as compared to normal cells, because glucose 
metabolism is increased in tumor cells. [18F]FDG PET-CT has been found to be useful in lesion detection 
and characterization, evaluation of tumor stage, assessment of treatment response and detection of 
recurrent disease [2, 3]. However, the specificity of this technique is low in patients with active infections 
and inflammatory diseases (because of high FDG uptake in macrophages) and in the brain (because of 
high background FDG uptake) [4, 5]. Therefore, the development of post-FDG radiopharmaceuticals is 
needed. 
After glucose transport, amino acid transport is another important pathway in cellular energy 
metabolism. Therefore, natural or artificial amino acid analogs have been widely studied clinically as 
potential post-FDG radiopharmaceuticals for PET imaging; One of the most important radiolabeled 
amino acids in this regard is [S-methyl-11C]-L-methionine ([11C]MET) [6, 7]. Since both amino acid 
transport and protein synthesis rates are enhanced in tumors, [11C]MET has been as widely used in brain 
tumor imaging as O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) [8, 9]. 
Numerous amino acid transporters have been identified at the molecular level and have been 
characterized in mammalian cells [10-12]. The main transport systems for the uptake of neutral amino 
acids are the A, L, and alanine-serine-cysteine (ASC) amino acid transport systems. System L amino acid 
transporters are Na+ independent, and are the main transport mechanism for methionine, tyrosine, 
phenylalanine, and their analogs such as FAMT (3-fluoro-α-methyl-tyrosine) [13-16]. The system A and 
ASC amino acid transporters are Na+-dependent, however, compared to the system L transporters, their 
involvement in the transport by radiolabeled amino acids in nuclear medicine has not been studied in 
detail. 
The artificial amino acid radiopharmaceutical α-[N-methyl-11C]-methylaminoisobutyric acid 
([11C]MeAIB) is a promising specific substrate of system A amino acid transport. Compared with 
[11C]MET, [11C]MeAIB is metabolically stable [17] and it has been studied both pre-clinically and 
clinically. For example, [11C]MeAIB has been shown to be useful in the measurement of amino acid 
uptake into skeletal muscle and in the diagnosis of malignant lymphoma and head and neck cancers 
[18-20]. In our institute, [11C]MeAIB PET has proven useful in the diagnosis of chest diseases, especially 
in the differential diagnosis between sarcoidosis and metastasis [21]. 
Previous studies in carcinoma cells have shown that there is a high correlation between both MET 
and FAMT uptake and the gene expression levels of system L amino acid transporters [15, 16, 22]. 
However, the relationship between the accumulation of radiolabeled amino acids and the gene expression 
levels of system A amino acid transporters has not been examined. 
In this study, we explored the amino acid transport systems in four different human carcinomas 
cell lines using α-[1-14C]-methylaminoisobutyric acid ([14C]MeAIB) as a substrate and comparing it to 
[S-methyl-3H]-L-methionine ([3H]MET) and [methyl-3H]-3'-deoxy-3'-fluorothymidine ([3H]FLT). We 
elected to use 14C or 3H-labeled amino acid analogs because both [11C]MeAIB and [11C]MET have a very 
short half-life (20 min). We also investigated the gene expression profiles of numerous amino acid 
transporters in these four types of human carcinoma cell lines using microarray analysis. Following on 
from this initial screen we used quantitative reverse transcription polymerase chain reaction (qRT-PCR) to 
characterize the expression of the mRNAs encoding SNAT1, SNAT2, SNAT4, ASCT1, ASCT2, y+LAT1, 
y+LAT2, LAT1, LAT2, LAT3, LAT4, and 4F2hc. We then examined the correlation between accumulation 
of [3H]MET and the quantitative mRNA expression of total system L transporter (total LAT= LAT1 + 
LAT2 + LAT3 + LAT4) and total system A amino acid transporters (total SNAT = SNAT1 + SNAT2 + 
SNAT4) in these human carcinoma cell lines. Finally, we examined the correlation between accumulation 
of [3H]FLT uptake and [14C]MeAIB uptake as well as the correlation between [3H]FLT uptake and the 
quantitative gene expression of total SNAT transporters.
2. Materials and methods 
2.1. Radiolabeled amino acid analogs and amino acid transport inhibitors 
Because of the short half-life of 11C (20 min), radiolabeled amino acid analogs with much longer 
half-lives were used instead. 14C-labeled MeAIB ([14C]MeAIB, 37 kBq/ml), 3H-labeled MET ([3H]MET, 
18.5 kBq/ml) and 3H-labeled FLT ([3H]FLT, 18.5 kBq/ml) were obtained from American Radiolabeled 
Chemicals Inc. (St Louis, Missouri, USA). MeAIB (α-methylaminoisobutyric acid), a specific inhibitor of 
system A, and BCH (2-amino-2-norbornane-carboxylic acid), a specific inhibitor of system L, were 
acquired from Sigma-Aldrich Japan KK (Tokyo, Japan). 
 
2.2. Cell culture 
Cell line studies were performed using a modification of the methods described by Shikano et al. 
and Nakajima et al. [23, 24], as follows. A431 and LS180 cell lines were purchased from Dainippon 
Sumitomo Pharma Co., Ltd (Osaka, Japan). The cultured human tumor cell lines H441 and PC14 were 
obtained from the University of Texas, MD Anderson Cancer Center, Houston, TX, USA. All cells were 
cultured in 150 mm cell culture dishes (Becton Dickinson, New Jersey, USA)  in a 5% CO2 humidified 
atmosphere at 37°C with specific media as follows; A431 cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM; Sigma-Aldrich, Japan) containing high glucose supplemented with 10% fetal 
bovine serum (FBS) and 3.7 g/L NaHCO3, H441 cells were maintained in RPMI-1640 medium 
(Sigma-Aldrich, Japan) supplemented with 10% FBS, 1% sodium pyruvate (Sigma-Aldrich, Japan) and 
2.0 g/L NaHCO3, PC14 cells were maintained in DMEM/Nutrient Mixture F-12 Ham (DMEM/F12; 
Sigma-Aldrich, Japan) supplemented with 10% FBS and 1.2 g/L NaHCO3, and LS180 cells were 
maintained in minimum essential medium Eagle (MEM; Sigma-Aldrich, Japan) supplemented with 10% 
FBS, 1% sodium pyruvate and 2.2 g/L NaHCO3. Sub-culturing was performed every five days using 
0.02% EDTA and 0.05% trypsin. For amino acid uptake experiments, cells were seeded into a 24-well 
Multiwell Plate (Becton Dickinson, New Jersey, USA) at a density of 5×105 cells/well and were used 24 
h after plating. 
 
2.3. Measurement of [14C]MeAIB, [3H]MET and [3H]FLT transport in human carcinoma cells 
For transport studies in a sodium-containing medium, phosphate-buffered saline (PBS) pH 7.4 
(137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1.5 mM K2HPO4, 1 mM CaCl2 and 0.5 mM MgCl2) was 
used. For sodium-free transport studies, the NaCl and Na2HPO4 in PBS were replaced with the same 
concentrations of choline-Cl and K2HPO4, respectively. After removal of the culture medium, the 24-well 
Multiwell Plate was washed once with 5 mL of incubation medium for 10 min at 37°C. The cells were 
then incubated with 500 µL/well of incubation medium containing [14C]MeAIB (37 kBq/mL) and 
[3H]MET (18.5 kBq/mL) or [3H]FLT (18.5 kBq/mL) for 10 min at 37°C. For the experiment involving 
amino acid transport, inhibitors were added to a final concentration of 1 mM, and the cells were then 
incubated for 10 min at 37°C with [14C]MeAIB (37 kBq/mL) and [3H]MET (18.5 kBq/mL) or [3H]FLT 
(18.5 kBq/mL). After incubation with the radiolabeled amino acid analog, the medium was aspirated and 
the monolayers were rapidly rinsed twice with 500 µL of ice-cold incubation medium. Cells were 
solubilized in 500 µL of 0.1N NaOH, and the radioactivity (either 3H and 14C) of an aliquot (400 µL) was 
measured by addition of Clear-Sol II (Nacalai Tesque Inc., Kyoto, Japan) and scintillation counting using 
a LSC-5100 liquid scintillation counter (Hitachi Aloka Medical, Ltd., Tokyo, Japan ). 
To characterize relative contributions of each type of transport system to overall amino acid 
analog uptake, we performed inhibition experiments with inhibitors as described above. BCH was used as 
a system L inhibitor and MeAIB was used as a system A inhibitor. To calculate the relative contributions 
of amino acid transporter systems, we used the methods reported by Shikano et al. [23] and Nakajima et 
al. [24]. In brief, uptake of [3H]MET and [14C]MeAIB in the absence of inhibitors was used as the control 
(100%). System A uptake was calculated as [control uptake in Na+-PBS] – [uptake in the presence of 
MeAIB in Na+-PBS]. Uptake by system ASC and/or other systems (for example IMINO, B0, G-like, N, 
and y+L which cannot be individually assessed yet) was calculated as [uptake in the presence of MeAIB 
in Na+-PBS] – [control uptake in Na+ free-PBS]. System L uptake was calculated as [control uptake in 
Na+ free-PBS] – [uptake in the presence of BCH in Na+ free-PBS]. 
 
2.4. DNA microarray and Quantitative real-time PCR 
DNA microarray and quantitative real-time PCR were performed using the method s of Okudaira 
et al. [25] and Yoshimoto et al. [26] The quality of RNA preparations was assessed using RIN (RNA 
Integrity Number) software tool on an Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, 
USA). The expression levels of neutral amino acid transporters in the four types of human carcinoma 
cells were analyzed using a DNA microarray (Agilent Technologies). The values are expressed as relative 
quantities to a Universal reference RNA (Stratagene Products Division, Agilent Technologies). 
mRNA levels of neutral amino acid transporters were determined by conducting qRT-PCR assays. 
Amplification and real-time fluorescence detection were performed using a model Mx3005P Real Time 
QPCR system (Stratagene Products Division, Agilent Technologies). All data were normalized using the 
geometric mean of β-actin and GAPDH. All reactions were performed in triplicate.
3. RESULTS 
3.1. Uptake of [14C]MeAIB, [3H]MET and [3H]FLT transport in human carcinoma cells. 
As shown in Fig. 1 for all four carcinoma cell lines the uptake of [3H]MET under control 
conditions (Na+-PBS) was found to be about 3-5 times higher than the uptake of either [14C]MeAIB. The 
uptake of [14C]MeAIB relative to [3H]FLT varied between the different cell lines with [3H]FLT showing 
greater uptake than [14C]MeAIB in A431 and PC14 cells and [14C]MeAIB showing greater uptake than 
[3H]FLT in H441 and LS180 cells. 
 
3.2. Competitive inhibition studies using [3H]MET and [14C]MeAIB. 
The majority of [3H]MET transport appeared to occur in a Na+-independent manner in all four 
carcinoma cell lines (Fig. 2). The inhibitor BCH caused a large significant inhibition of this 
Na+-independent transport indicating the importance of system L. Although, the system A inhibitor 
MeAIB showed significant inhibition of Na+-dependent transport in H441, PC14, and LS180 cells, the 
absolute magnitude of inhibition was very small relative to the magnitude of inhibition seen with BCH. 
The contribution of system A to MET uptake is therefore small relative to the contribution of system L. 
By comparing the uptake in MeAIB treated cells in the presence of Na+ with uptake in control medium 
lacking Na+ the relative contribution of system ASC and/or other systems to MET uptake can be 
calculated. The ASC system was found to have a significant contribution to MET transport in PC14 and 
LS180 cells but not in A431 or H441 cells, although as for system A, the relative magnitude was less than 
system L. 
In contrast, in all four carcinomas, the majority of [14C]MeAIB uptake was Na+ dependent (Fig. 3) 
and as expected there was a large and significant inhibition of this Na+ dependent uptake of [14C]MeAIB 
by MeAIB indicating the importance of system A. The system L inhibitor had either no or minimal effect 
on the remaining Na+-independent transport. 
 
3.3. Relative contribution of amino acid transport systems for MET and MeAIB in human carcinomas. 
The relative contributions of amino acid transport systems A, L, and, ASC/other to the uptake of 
[3H]MET and [14C]MeAIB in the four types of human carcinomas were estimated using the modified 
methods of Shikano et al. [23] and Nakajima et al. [24] and the results are shown in Table 1. Although the 
dominant uptake mechanism for [3H]MET in human carcinomas was through system L amino acid 
transport, system A, ASC, or other Na+-dependent system(s) also played a role. The dominant uptake 
mechanism of [14C]MeAIB in human carcinomas was Na+-dependent and occurred via system A. 
 
3.4. Correlation between [3H]MET and [14C]MeAIB uptake and transporter gene expression or [3H]FLT 
in human-derived tumor cells. 
With regard to the contribution of system L amino acid transport to the Na+-dependent uptake of 
[3H]MET the A431 and H441 cells had the highest system L contribution (76.3%and 48.9% respectively). 
(Table 1). When the expression of numerous sodium-dependent and -independent amino acid transporters 
were analyzed using microarray gene expression profiling, as well as by qRT-PCR, the expression of the 
system L transporter LAT1 and the coupling factor 4F2hc were found to be abundantly expressed in both 
A431 and H441 cells compared to the PC14 and LS180 cells (Table 2 and Table 3). Based on the results 
of the qRT-PCR analysis, the expression of LAT1 varied across the four different carcinoma cell lines 
(Table 4). When the [3H]MET uptake in the presence of Na+ for all four carcinomas was plotted against 
total LAT (system L) expression no correlation was found (Fig. 4A). On the other hand, there was a 
significant correlation between accumulation of [14C]MeAIB and total SNAT (system A) gene expression 
in the carcinoma cells (Fig. 4B). Moreover, there are significant correlations between accumulation of 
[3H]FLT and accumulation of [14C]MeAIB as well as between [3H]FLT accumulation and gene 
expression level of the system A amino acid transporter SNAT in the carcinoma cells (Fig. 5C and D). 
For [3H]MET, the R2 value between accumulation of [3H]FLT and accumulation of [3H]MET was lower 
comparison with [14C]MeAIB (Fig. 5A and C). There was no correlation between accumulation of 
[3H]FLT and gene expression of the total system L amino acid transporter (LAT) expression (Fig. 5B). 
 
3.5. Statistical Analysis 
Data are presented as means and ± SDs. P values were calculated using a two-tailed paired 
Student t test for comparison between two groups. A P value less than 0.05 was considered significant. 
4. Discussion 
The amino acid analog MeAIB is an inhibitor and specific substrate for system A amino acid 
transport and the main transport mechanism for MeAIB uptake is thought to occur via system A [27-32]. 
A study in Chinese hamster ovary (CHO) cells showed that more than 90% of MeAIB transport occurred 
through system A [9, 33]. A study in cultured human erythroleukemic (K562) cells using radiolabeled 
[14C]MeAIB also gave the same result [34]. Given all of data, it is thought that system A is the principal 
[11C]MeAIB transport pathway in in vivo human PET studies [19, 20], although no human PET study has 
been conducted in the presence of amino acid transport inhibitors. In our study using four different types 
of human carcinoma cells we have shown that system A contributes more than 70% to [14C]MeAIB 
uptake. In contrast the uptake of [3H]MET was less specific; although system L was the predominant 
mechanism there were contributions of both system A and system ASC and the relative contributions of 
all systems varied between the different cell lines (Table 1). Stability studies have shown that more than 
95% of [11C]MeAIB remained unchanged in human plasma 30 minutes after administration. Since it is an 
unnatural amino acid, it also cannot be used for protein synthesis [17]. Therefore, [11C]MeAIB imaging 
may more accurately represent the uptake of amino acid transporter system A compared to [11C]MET. 
Since [11C]MeAIB has higher selectivity for system A compared to [11C]-2-aminoisobutyric acid 
([11C]AIB, another system A substrate) [27, 31], [11C]MeAIB is expected to be very useful in system A 
amino acid transport PET imaging. We have previously reported the utility of [11C]MeAIB in the 
diagnosis of chest diseases, especially in the differential diagnosis between sarcoidosis and metastasis 
[21]. [11C]MeAIB has comparable sensitivity to [18F]FDG PET for the diagnosis of prostate cancer [35] 
and the tumor/non-tumor ratio obtained with [11C]MeAIB precisely distinguishes the malignant group 
from the benign group in patients with brain tumors [36]. 
On the other hand, the main transport mechanism of [3H]MET in tumor cells has been reported to 
be system L [21, 35], which is consistent with our study results. The radiolabeled amino acid [11C]MET 
has the [11C] group incorporated into the methyl group attached to the sulfur. [11C]MET is used at a lower 
rate in protein synthesis compared with other [11C] labeled amino acids such as [1-11C]-L-methionine 
which has the label in the carboxyl terminal. Therefore, [11C]MET tumor uptake represents a combination 
of amino acid transport and intracellular metabolism [37]. However, since radiosynthesis of [11C]MET is 
extremely simple and easy, in clinical practice, [11C]MET-PET, together with [18F]FET, has been widely 
used in brain tumor imaging [8, 9]. 
We investigated the correlation between accumulation of [3H]MET and [14C]MeAIB in four types 
of human carcinoma cells and gene expression, which led to the conclusion that there was no correlation 
between [3H]MET uptake and LAT expression (Fig. 4A). A weak relationship between [3H]MET uptake 
and total LAT expression has previously been reported [22, 26]. The reasons for this lack of correlation 
are not completely clear but could perhaps be related to the fact that LAT1 biology is complex and 
involves a number of other proteins. One such protein is the amino acid transporter activating factor 
4F2hc with which LAT1 forms disulfide-linked heterodimers thereby becoming active. A second protein 
is ASCT2. LAT1 transports neutral amino acid with long side chains, such as leucine, and simultaneously 
counter transports intracellular glutamine [38, 39]. The intracellular glutamine supply is maintained via 
the intracellular Na+-dependent amino acid transporter ASCT2 that helps facilitate LAT1 function. The 
interplay between LAT1, ASCT2, and 4F2hc is thought to be important in controlling cancer cell 
metabolism [40]. For example, co-expression of LAT1 with ASCT2 has been shown in lung cancer, and 
this co-expression, but not the sole expression of LAT1 or ASCT2, is strongly related to prognosis [41]. 
In our study, [14C]MeAIB accumulation in four types of human carcinoma cells was correlated 
with total SNAT expression (Fig. 4B). Since SNAT does not require an activating factor, there is a high 
possibility of a consistent relationship between SNAT expression and cellular uptake. System L, which 
transports amino acids into cells, has a counter transport mechanism associated with it. In contrast, system 
A, which also transports amino acids into cells, has no counter transport activity. Amino acid transporter 
function can therefore be evaluated directly using MeAIB (system A substrate), allowing differentiation 
from system L [42, 43]. The correlation between the uptake of radiotracers and the gene expression of 
amino acid transporter in tumor cells has been evaluated in a number of recent nuclear medicine studies. 
A correlation between 4-borono-2-18F-fluoro-phenylalanine ([18F]FBPA) and L-3-[18F]fluoro-α-methyl 
tyrosine ([18F]FAMT) uptake and LAT1 expression [15, 16, 26], a correlation between 
[S-methyl-3H]-D-MET uptake and LAT + ASCT expression [22], and a correlation between 
Trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid ([18F]FACBC) uptake and ASCT expression [25, 
44] have all been recently reported. However, it should be borne in mind that gene expression levels may 
not directly correlate with protein levels. In addition, cell-surface localization and activity of amino acid 
transporter proteins may not necessarily be predicted by gene expression levels. 
Our data also showed that [3H]FLT accumulation was strongly correlated with SNAT expression 
and [14C]MeAIB accumulation (Fig. 5C and D). Uptake of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), 
followed by phosphorylation by Thymidine Kinase 1 (TK1) leads to accumulation of the phosphorylated 
form of [18F]FLT in cells. The TK1 activity of cells has been reported to be related to cellular proliferative 
activity, which can be easily evaluated based on [18F]FLT accumulation [45-47]. Based on these data, 
since [3H]FLT accumulation is correlated with [14C]MeAIB accumulation, it is reasonable to conclude 
that [11C]MeAIB accumulation is correlated not only with SNAT expression but also with cellular 
proliferative activity. For [3H]MET, the R2 value between accumulation of [3H]FLT and accumulation of 
[3H]MET was lower comparison with [14C]MeAIB (Fig. 5A and C). From the perspective of statistics, it 
needs to be examined correlation of [3H]FLT uptake with either [3H]MET uptake or [14C]MeAIB uptake 
in many human carcinoma cells. Studies using Ki-67 in many human carcinoma cells are underway to 
confirm the uptake results observed correlating [14C]MeAIB and [3H]MET to [3H]FLT uptake. 
Glucose metabolism, as well as amino acid metabolism, increases as a requirement to supply an 
energy source for cell proliferation in cancer cells [48]. Moreover, amino acids and amino acid 
transporters play important roles other than in energy metabolism, such as in macromolecular synthesis, 
mTOR activation, and ROS homeostasis beyond energy metabolism [49]. There are approximately fifty 
different types of amino acid transporters, but only LAT1 [50], LAT3 [51], ASCT2 [52], ATB0, + [53] and 
xCT [54] have been reported to be expressed at high levels on the surface of cancer cells. Recently, there 
have been numerous reports in cancer cells related to glutamine transport via ASCT2 and LAT1 [55-57]. 
Moreover, the expression levels of the SNAT amino acid transporter, which belongs to the SLC38 family 
and like ASCT2 and LAT1 is related to glutamine transport, have been examined in a range of different 
cancers. Overexpression of SNAT was observed in gastric cancer [58], human hepatocellular carcinoma 
[59], breast cancer [60, 61], hilar cholangiocarcinoma [62], C6 glioma [63], prostate cancer [25], HeLa 
epithelial cervical cancer cells, and 143B osteosarcoma cells [64]; and SNAT expression in stomach and 
breast cancers is also related to Ki-67 [61] and PCNA (proliferating cell nuclear antigen) expression [58] 
as indicated by proliferative activity. 
Reportedly, the accumulation of [11C]AIB, an unnatural amino acid and amino acid transporter 
system A substrate, accumulation in cancer cells post-radiation therapy is correlated with changes in 
SLC38A1 expression [65]. Data from the Oncomine analysis (a gene expression database of 947 human 
cancer cell lines, http://www.broadinstitute.org/ccle) revealed that ASCT2, SNAT1 and SNAT2 were 
overexpressed, which could lead to a new treatment for preventing proliferation of cancer cells [64]. The 
studies reported here highlight the potential importance of SNAT in cancer. As described earlier, there 
have been an increasing number of studies highlighting the role of SNAT in cancer cells. Since 
[11C]MeAIB accumulation is correlated with SNAT expression and SNAT expression is correlated with 
[18F]FLT accumulation in cancer cells, this suggests there is a relationship with tumor proliferative 
activity. 
Our results along with previous investigations support the concept that SNAT mediates the uptake 
of [11C]MeAIB by tumor cells. We expect that accurate PCR studies examining the relationship between 
amino acid transporter gene expression and amino acid transporter activity in human carcinoma cells will 
be performed in the future. 
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Figure Legends 
Figure 1. Uptake of [14C]MeAIB, [3H]MET, and [3H]FLT by four human carcinoma cell lines. Uptake of 
radiolabeled amino acid analogs in the presence of Na+ was measured 10 min after addition to four 
different carcinoma cell lines. Data are expressed as %ID/105 cells. Error bars represent s.d. (n = 4). ID 
injected dose. 
 
Figure 2. Effect of Na+ and selective amino acid transport inhibitors on the uptake of [3H]MET by four 
human carcinoma cell lines. Uptake of [3H]MET by four different cell lines was measured under the 
following conditions; (i) in the presence of Na+ (Na+-PBS) and either the absence or presence of the  
transport inhibitor MeAIB at a final concentration of 1 mM (Control/Na+-PBS and MeAIB/Na+-PBS 
respectively) and (ii) in the absence of Na+ (Na+-free PBS) and either the presence or absence of the 
transport inhibitor BCH at a final concentration of 1 mM (Control/Na+ free-PBS and BCH/ Na+ free-PBS 
respectively). As shown for the PC14 cell line, system A uptake was calculated as [control uptake of 
[3H]MET in Na+-PBS] – [uptake of [3H]MET in the presence of MeAIB in Na+-PBS]. Uptake by system 
ASC and/or other systems was calculated as [uptake of [3H]MET in the presence of MeAIB in Na+-PBS] 
– [control uptake of [3H]MET in Na+ free-PBS]. System L uptake was calculated as [control uptake of 
[3H]MET in Na+ free-PBS] – [uptake of [3H]MET in the presence of BCH in Na+ free-PBS]. Data are 
expressed as %ID/105 cells. Error bars represent s.d. (n = 4). *P<0.05 and **P<0.005, NS not significant. 
ID injected dose. 
 
Figure 3. Effect of Na+ and selective amino acid transport inhibitors on the uptake of [14C]MeAIB by four 
human carcinoma cell lines. Uptake of [14C]MeAIB by four different cell lines was measured under the 
following conditions; (i) in the presence of Na+ (Na+-PBS) and either the absence or presence of the 
transport inhibitor MeAIB at a final concentration of 1 mM (Control/Na+-PBS and MeAIB/Na+-PBS 
respectively) and (ii) in the absence of Na+ (Na+-free PBS) and either the presence or absence of the 
transport inhibitor BCH at a final concentration of 1 mM (Control/Na+ free-PBS and BCH/ Na+ free-PBS 
respectively). As shown for the A431 cell line, system A uptake was calculated as [control uptake of 
[14C]MeAIB in Na+-PBS] – [uptake of [14C]MeAIB in the presence of MeAIB in Na+-PBS]. Uptake by 
system ASC and/or other systems was calculated as [uptake of [14C]MeAIB in the presence of MeAIB in 
Na+-PBS] – [control uptake of [14C]MeAIB in Na+ free-PBS]. System L uptake was calculated as [control 
uptake of [14C]MeAIB in Na+ free-PBS] – [uptake of [14C]MeAIB in the presence of BCH in Na+ 
free-PBS]. Data are expressed as %ID/105 cells. Error bars represent s.d. (n = 4). *P<0.01, **P<0.05, 
***P<0.005, NS not significant. ID injected dose. 
 
Table 1. Relative functional contributions of different amino acid transport systems in four human 
carcinoma cells. Uptake of [3H]MET and [14C]MeAIB in the absence of inhibitors was used as the control 
(100%). System A uptake was calculated as [control uptake in Na+-PBS] – [uptake in the presence of 
MeAIB in Na+-PBS]. Uptake by system ASC and/or other systems was calculated as [uptake in the 
presence of MeAIB in Na+-PBS] – [control uptake in Na+ free-PBS]. System L uptake was calculated as 
[control uptake in Na+ free-PBS] – [uptake in the presence of BCH in Na+ free-PBS]. 
 
Table 2. Microarray gene expression profiling of sodium-dependent and -independent amino acid 
transporters in four human carcinoma cell lines. 
 
Table 3. Absolute quantification of sodium-dependent and -independent amino acid transporters. 
 
Figure 4. Correlation between gene expression levels of system A and system L amino acid transporters 
and uptake of [3H]MET and [14C]MeAIB in human carcinomas. The figures show the relationship 
between [3H]MET uptake and the gene expression levels of total amino acid transporter system L (total 
LAT) (A) and between [14C]MeAIB uptake and gene expression levels of total amino acid transporter 
system A (total SNAT) (B). A431 (●), H441 (▲), PC14 (■) and LS180 (○). Tumor cell uptake of 
[14C]MeAIB showed a high correlation with the levels of gene expression of amino acid transport system 
A. *P<0.05 
 
Figure 5. Correlation of [3H]FLT uptake with either [3H]MET uptake, the gene expression levels of amino 
acid transporter system L, either [14C]MeAIB uptake or the gene expression levels of amino acid 
transporter system A in human carcinomas. The figures show the relationship between [3H]FLT uptake 
and [3H]MET uptake (A), between [3H]FLT uptake and the gene expression levels of total amino acid 
transporter system L (total LAT) (B), between [3H]FLT uptake and [14C]MeAIB uptake (C) and between 
[3H]FLT uptake and the gene expression levels of total amino acid transporter system A (total SNAT) (D). 
A431 (●), H441 (▲), PC14 (■) and LS180 (○). Tumor cell uptake of [3H]FLT showed a high correlation 
with [14C]MeAIB uptake and with the total gene expression levels of amino acid transport system A (total 
SNAT) and no correlation with the total gene expression levels of amino acid transport system L (total 
LAT). *P<0.05, **P<0.025, ***P<0.001
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*P<0.05 **P<0.01 ***P<0.005
Table 1 
System ASCCells System A   and/or others System L
A431 － － 76.3%
3H-MET
H441 15.8% － 48.9%
PC14 15 0% 21 2% 38 5%. . .
LS180 13.7% 13.7% 38.5%
14
A431 76.8% 7.1% 3.6%
H441 76.1% 9.8% －
C-MeAIB
PC14 71.5% 14.4% －
LS180 73 9% 10 5% －. .
% of control
Table 2
System Transporter A431 H441 PC14 LS180
A
SNAT1 1.233 0.938 0.687 0.383 1.148 1.128 0.553 1.022 
SNAT2 0.448 0.319 0.835 0.190 1.022 0.654 1.740 0.382 
SNAT4 0.148 0.298 0.143 0.491 0.286 0.587 0.268 0.389 
SNAT6 3.860 1.407 2.324 0.252 
GLY GlyT1 5.004 4.089 1.305 0.938 GlyT2 0.575 0.693 0.836 0.470 
1 355 3 487 0 432 1 036
sodium-dependent ASC
ASCT1 .  .  .  .  0.644 1.360 0.174 0.395 
ASCT2 3.536 1.860 0.896 2.097 
N SNAT3 0.285 0.100 0.254 0.249 SNAT5 10.941 5.275 0.019 0.037 
β T 0.348 0.157 0.829 0.398aut     1.102 0.723 2.296 2.622 
B0 B0AT 0.047 0.023 0.023 1.302 0.080 0.164 0.074 0.850 
y+L
y+LAT1 0.167 0.184 36.885 46.218 
+
1.882 0.572 2.559 3.589 
y LAT2 0.618 1.012 1.235 0.694 
0.942 0.931 1.381 1.220 
L
LAT1 2.700 7.329 0.244 1.197 4.981 11.428 0.166 1.693 
LAT2 0.540 2.500 0.014 1.309 
LAT3 0 193 0 669 0 753 5 427sodium-independent .  .  .  .  LAT4 0.106 0.182 0.057 0.569 
T TAT1 0.116 3.366 0.332 0.159 
B0 BAT1 0.166 0.337 0.156 0.227 
asc asc1 0.065 0.134 0.059 0.086 
coupling facter L y+L asc X C 4F2hc 4.682 9.485 0.637 1.946  , , , - 4.646 9.681 0.560 1.939 
Table 3
System Transporter A431 H441 PC14 LS180
A
SNAT1 1.341 0.917 0.767 0.915 
SNAT2 0 407 0 306 0 814 0 203
sodium-dependent
.  .  .  .  
SNAT4 0.001 0 0 0.004 
ASC
ASCT1 0.110 0.236 0.034 0.083 
ASCT2 1.452 0.659 0.300 0.893 
y+L
y+LAT1 0 0 0.066 0.084 
y+LAT2 0.038 0.016 0.055 0.119 
LAT1 2.384 5.688 0.064 0.768 
A 2 0 040 0 1 9 0 111
sodium-independent L
L T .  . 7  - .  
LAT3 0 0.006 0.007 0.051 
LAT4 0.005 0.008 0.002 0.037 
system L cofactor 4F2hc 4F2hc 4.337 10.085 0.508 2.171      
copy / 10 copy of  housekeeping gene
1.0 
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Fig. 4 *P<0.05
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Gene expression of system A
(copy / 10 copy of housekeeping gene)
MeAIB uptake (% uptake/105 cells)
*P<0.05     **P<0.025     ***P<0.001
Supplemental date 1
Gene Primer Length Position Sequence Amplicon size
SNAT1 Forward 19 1373 - 1391 attttgggactcgcctttg Amplicon (77 nt)
Reverse 24 1426 - 1449 agcaatgtcactgaagtcaaaagt
SNAT2 Forward 26 1738 - 1763 cctatgaaatctgtacaaaagattgg Amplicon (104 nt)
Reverse 22 1820 - 1841 ttgtgtacccaatccaaaacaa 
SNAT4 Forward 20 1794 - 1813 tgttctggtcatccttgtgc Amplicon (96 nt)
Reverse 26 1864 - 1889 aaaactgctggaagaataaaaatcag
ASCT1 Forward 20 1190 - 1209 tttgcgacagcatttgctac Amplicon (60 nt)
Reverse 22 1228 - 1249 gcacttcatcatagagggaagg
Forward 20 1220 - 1239 gaggaatatcaccggaaccaASCT2  Amplicon (66 nt)
Reverse 19 1267 - 1285 aggatgttcatcccctcca
y+LAT1 Forward 21 142 - 162 cctgcttatatccaggaccaa Amplicon (96 nt)
Reverse 21 217 - 237 ggccacttcatactcagtgct
y+LAT2 Forward 23 1405 - 1427 cctatccctgctttactgttcaa Amplicon (89nt)
Reverse 25 1469 1493 aagctgaagtagttgataagctgga -
LAT1 Forward 20 1503 - 1522 gtggaaaaacaagcccaagt Amplicon (71nt)
Reverse 20 1554 - 1573 gcatgagcttctgacacagg
LAT2 Forward 20 480 - 499 ttgccaatgtcgcttatgtc Amplicon (87 nt)
Reverse 22 545 - 566 ggagcttctctccaaaagtcac
F d 19 686 704 ttt t t t tLAT3 orwar  - gg ggca c gcc aa Amplicon (74 nt)
Reverse 19 741 - 759 attaacgtggagcgcaggt
LAT4 Forward 18 1620 - 1637 cagggagaccctctgtgg Amplicon (86 nt)
Reverse 21 1685 - 1705 cggtagcagatcaggtagagc
4F2hc Forward 19 1251 - 1269 taccggggtgagaactcgt Amplicon (81 nt)
R 20 1312 1331 t teverse  - cagccaaaac ccagagca
ACTB Forward 18 414 - 431 ccaaccgcgagaagatga Amplicon (97 nt)
Reverse 20 491 - 510 ccagaggcgtacagggatag
GAPDH
Forward 19 83 - 101 agccacatcgctcagacac
Amplicon (66 nt)
Reverse 19 130 - 148 gcccaatacgaccaaatcc
